PERVASIVE HYPERMUTATION OF SUPER-ENHANCER REGIONS DYSREGULATES ONCOGENE EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA abstract
E Bal, R Kumar, M Hadigo, A Holmes, K Basso, H Khiabanian, L Pasqualucci, R Dalla-Favera
The study authors conclude that these data identify a highly pervasive mutational mechanism involving regulatory chromatin domains in DLBCL and the findings:
- reveal a new major set of genetic lesions deregulating gene expression, including known oncogenes, likely representing an important mechanism in DLBCL pathogenesis;
- expand the involvement of known oncogenes in DLBCL pathogenesis and identify new deregulated gene targets that may represent candidate therapeutic targets.
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE-ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B-CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09-1B TRIAL abstract
S Bologna, T Vander Borght, J Briere, V Ribrag, et al.
The study authors demonstrate with this study a non-inferiority of 4 cycles of R-CHOP versus 6 R-CHOP for early good responders, confirming that 4 R-CHOP could be the new standard of care of the large majority of limited-stage DLBCL patients. The occurrence of late relapses shows the need for long-term follow-up for all patients, even if the outcome is very good in this population.
DETERMINANTS OF RESISTANCE TO ENGINEERED T-CELL THERAPIES TARGETING CD19 IN LYMPHOMA abstract
B Sworder, D. M Kurtz, S Alig, M. J Frank,
The study authors conclude that baseline and interim ctDNA and CAR19-cfDNA measurements have prognostic significance in LBCL patients being treated with CAR19 T-cells. They further show that genomic alterations in several genes, including CD19, CD58, PAX5 and IRF8 are associated with inferior outcomes and thus represent candidate resistance mechanisms that warrant further study with the goal of improving future generations of CAR T-cell therapy.